I have gone through quite a few papers, and protocols. .Majority of the papers mention the addition of IL-2 to maintain Tregs in-vitro, however, some papers use both IL-2 and anti CD3. Which is the preferred methodology and why?
You may find protocols using IL-2 alone, aCD3+IL-2 and aCD3+aCD28+IL-2. The difference would be just maintenance vs. maintenance and expansion. So what to use will depend on what you want to achieve.